Here, we investigated the structural requirements of compounds that selectively inhibit PSEN1–γ-secretase complexes versus PSEN2–γ-secretases as those were shown to provide a therapeutic window in preclinical models of AD and T-ALL (7, 19, 21). This evidence concerns the gene PSEN2 and acute lymphoblastic leukemia.